Changjiang Pharmaceutical Group Co., Ltd. Logo

Changjiang Pharmaceutical Group Co., Ltd.

300391.SZ

(0.0)
Stock Price

6,21 CNY

-26.2% ROA

-274.37% ROE

-2.88x PER

Market Cap.

2.116.029.440,00 CNY

2350.45% DER

0% Yield

-92.39% NPM

Changjiang Pharmaceutical Group Co., Ltd. Stock Analysis

Changjiang Pharmaceutical Group Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Changjiang Pharmaceutical Group Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Negative ROE (-0.73%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (-0.2%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

3 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.83x) suggests it's overvalued, potentially making it an expensive investment.

4 DER

The stock is burdened with a heavy load of debt (120%), making it financially unstable and potentially risky for investors.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1.455) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Changjiang Pharmaceutical Group Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Changjiang Pharmaceutical Group Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Changjiang Pharmaceutical Group Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Changjiang Pharmaceutical Group Co., Ltd. Revenue
Year Revenue Growth
2009 128.131.531
2010 177.609.816 27.86%
2011 223.180.306 20.42%
2012 225.272.826 0.93%
2013 255.385.121 11.79%
2014 243.428.659 -4.91%
2015 191.250.584 -27.28%
2016 234.866.048 18.57%
2017 744.154.806 68.44%
2018 881.022.368 15.54%
2019 725.310.882 -21.47%
2020 1.214.503.960 40.28%
2021 2.361.946.450 48.58%
2022 1.615.322.934 -46.22%
2023 2.183.416.303 26.02%
2023 1.197.562.401 -82.32%
2024 55.467.596 -2059.03%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Changjiang Pharmaceutical Group Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 12.070.734 100%
2012 16.155.352 25.28%
2013 18.360.708 12.01%
2014 16.166.575 -13.57%
2015 21.541.010 24.95%
2016 25.425.226 15.28%
2017 33.888.711 24.97%
2018 33.492.264 -1.18%
2019 47.865.058 30.03%
2020 43.155.449 -10.91%
2021 39.363.616 -9.63%
2022 25.758.873 -52.82%
2023 9.888.925 -160.48%
2023 7.660.845 -29.08%
2024 4.634.056 -65.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Changjiang Pharmaceutical Group Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 22.333.966
2010 22.268.039 -0.3%
2011 3.939.112 -465.31%
2012 2.173.494 -81.23%
2013 3.463.406 37.24%
2014 2.994.239 -15.67%
2015 5.289.879 43.4%
2016 7.054.789 25.02%
2017 20.086.962 64.88%
2018 19.973.236 -0.57%
2019 38.293.455 47.84%
2020 48.060.778 20.32%
2021 47.439.414 -1.31%
2022 22.648.421 -109.46%
2023 164.126.411 86.2%
2023 54.622.340 -200.47%
2024 -42.148.341 229.6%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Changjiang Pharmaceutical Group Co., Ltd. EBITDA
Year EBITDA Growth
2009 32.479.864
2010 42.319.199 23.25%
2011 66.047.410 35.93%
2012 66.618.148 0.86%
2013 67.701.012 1.6%
2014 66.470.954 -1.85%
2015 31.945.920 -108.07%
2016 39.567.505 19.26%
2017 123.561.396 67.98%
2018 190.618.559 35.18%
2019 23.691.155 -704.6%
2020 131.235.202 81.95%
2021 344.363.556 61.89%
2022 352.884.987 2.41%
2023 188.761.461 -86.95%
2023 183.391.459 -2.93%
2024 -457.033.280 140.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Changjiang Pharmaceutical Group Co., Ltd. Gross Profit
Year Gross Profit Growth
2009 55.864.348
2010 72.176.019 22.6%
2011 84.955.824 15.04%
2012 89.655.102 5.24%
2013 98.468.850 8.95%
2014 89.394.155 -10.15%
2015 64.063.693 -39.54%
2016 76.459.889 16.21%
2017 221.278.431 65.45%
2018 279.910.363 20.95%
2019 181.570.919 -54.16%
2020 263.508.304 31.09%
2021 535.833.110 50.82%
2022 346.777.907 -54.52%
2023 336.564.199 -3.03%
2023 196.006.582 -71.71%
2024 -29.900.196 755.54%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Changjiang Pharmaceutical Group Co., Ltd. Net Profit
Year Net Profit Growth
2009 17.770.454
2010 30.808.332 42.32%
2011 37.133.207 17.03%
2012 35.477.991 -4.67%
2013 34.958.543 -1.49%
2014 28.718.706 -21.73%
2015 5.027.997 -471.18%
2016 4.221.139 -19.11%
2017 69.716.990 93.95%
2018 101.988.481 31.64%
2019 -669.698.128 115.23%
2020 25.319.988 2744.94%
2021 49.104.524 48.44%
2022 -23.273.315 310.99%
2023 -366.549.331 93.65%
2023 -605.653.315 39.48%
2024 -420.268.624 -44.11%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Changjiang Pharmaceutical Group Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 1
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -2 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 -2 100%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Changjiang Pharmaceutical Group Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2009 -844.055
2010 -1.615.197 47.74%
2011 -1.092.904 -47.79%
2012 -14.244.793 92.33%
2013 -38.051.014 62.56%
2014 -71.713.838 46.94%
2015 17.123.767 518.8%
2016 -31.820.888 153.81%
2017 34.910.006 191.15%
2018 128.248.505 72.78%
2019 17.064.814 -651.54%
2020 13.984.555 -22.03%
2021 88.723.672 84.24%
2022 -117.549.852 175.48%
2023 -154.216.742 23.78%
2023 -1.071.794 -14288.67%
2024 918.827 216.65%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Changjiang Pharmaceutical Group Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2009 21.348.500
2010 27.067.800 21.13%
2011 30.360.686 10.85%
2012 29.341.438 -3.47%
2013 21.658.761 -35.47%
2014 -38.880.883 155.71%
2015 40.984.292 194.87%
2016 -18.006.133 327.61%
2017 38.957.030 146.22%
2018 137.087.581 71.58%
2019 22.302.178 -514.68%
2020 32.805.640 32.02%
2021 230.987.890 85.8%
2022 -66.075.132 449.58%
2023 -147.425.872 55.18%
2023 0 0%
2024 2.688.827 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Changjiang Pharmaceutical Group Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2009 22.192.555
2010 28.682.997 22.63%
2011 31.453.590 8.81%
2012 43.586.231 27.84%
2013 59.709.775 27%
2014 32.832.954 -81.86%
2015 23.860.524 -37.6%
2016 13.814.756 -72.72%
2017 4.047.024 -241.36%
2018 8.839.076 54.21%
2019 5.237.364 -68.77%
2020 18.821.084 72.17%
2021 142.264.218 86.77%
2022 51.474.720 -176.38%
2023 6.790.870 -658%
2023 1.071.794 -533.6%
2024 1.770.000 39.45%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Changjiang Pharmaceutical Group Co., Ltd. Equity
Year Equity Growth
2009 70.624.509
2010 117.432.842 39.86%
2011 144.566.049 18.77%
2012 172.544.040 16.21%
2013 197.502.583 12.64%
2014 364.706.787 45.85%
2015 363.913.911 -0.22%
2016 362.880.552 -0.28%
2017 933.889.351 61.14%
2018 1.431.643.425 34.77%
2019 751.945.496 -90.39%
2020 1.449.481.440 48.12%
2021 1.609.295.136 9.93%
2022 1.664.620.818 3.32%
2023 1.587.064.676 -4.89%
2023 1.017.321.429 -56%
2024 775.616.266 -31.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Changjiang Pharmaceutical Group Co., Ltd. Assets
Year Assets Growth
2009 228.168.278
2010 278.035.752 17.94%
2011 329.721.056 15.68%
2012 407.276.720 19.04%
2013 562.919.130 27.65%
2014 681.847.082 17.44%
2015 694.641.061 1.84%
2016 748.109.466 7.15%
2017 1.968.962.399 62%
2018 2.084.243.883 5.53%
2019 1.523.130.740 -36.84%
2020 4.683.035.941 67.48%
2021 4.214.473.787 -11.12%
2022 3.578.587.920 -17.77%
2023 3.742.686.088 4.38%
2023 3.445.757.061 -8.62%
2024 3.107.809.704 -10.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Changjiang Pharmaceutical Group Co., Ltd. Liabilities
Year Liabilities Growth
2009 157.543.769
2010 160.602.910 1.9%
2011 185.155.006 13.26%
2012 234.732.680 21.12%
2013 365.416.546 35.76%
2014 317.140.295 -15.22%
2015 330.727.149 4.11%
2016 385.228.913 14.15%
2017 1.035.073.047 62.78%
2018 652.600.457 -58.61%
2019 771.185.243 15.38%
2020 3.233.554.499 76.15%
2021 2.605.178.650 -24.12%
2022 1.913.967.101 -36.11%
2023 2.155.621.413 11.21%
2023 2.428.435.632 11.23%
2024 2.317.114.970 -4.8%

Changjiang Pharmaceutical Group Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.27
Net Income per Share
-2.1
Price to Earning Ratio
-2.88x
Price To Sales Ratio
2.66x
POCF Ratio
-11.16
PFCF Ratio
-10.75
Price to Book Ratio
49.73
EV to Sales
3.92
EV Over EBITDA
-29.63
EV to Operating CashFlow
-16.41
EV to FreeCashFlow
-15.81
Earnings Yield
-0.35
FreeCashFlow Yield
-0.09
Market Cap
2,12 Bil.
Enterprise Value
3,11 Bil.
Graham Number
2.39
Graham NetNet
-2.99

Income Statement Metrics

Net Income per Share
-2.1
Income Quality
0.26
ROE
-2.74
Return On Assets
-0.24
Return On Capital Employed
-0.56
Net Income per EBT
0.83
EBT Per Ebit
1.18
Ebit per Revenue
-0.94
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.14
Operating Profit Margin
-0.94
Pretax Profit Margin
-1.11
Net Profit Margin
-0.92

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.09
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.54
Free CashFlow per Share
-0.56
Capex to Operating CashFlow
-0.04
Capex to Revenue
0.01
Capex to Depreciation
0.16
Return on Invested Capital
-0.67
Return on Tangible Assets
-0.26
Days Sales Outstanding
755.65
Days Payables Outstanding
174.68
Days of Inventory on Hand
29.06
Receivables Turnover
0.48
Payables Turnover
2.09
Inventory Turnover
12.56
Capex per Share
0.02

Balance Sheet

Cash per Share
0,03
Book Value per Share
2,26
Tangible Book Value per Share
1.38
Shareholders Equity per Share
0.12
Interest Debt per Share
3.11
Debt to Equity
23.5
Debt to Assets
0.32
Net Debt to EBITDA
-9.48
Current Ratio
1.03
Tangible Asset Value
0,48 Bil.
Net Current Asset Value
-0,48 Bil.
Invested Capital
1305680399
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.1
Average Receivables
1,63 Bil.
Average Payables
0,34 Bil.
Average Inventory
53928280
Debt to Market Cap
0.47

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Changjiang Pharmaceutical Group Co., Ltd. Dividends
Year Dividends Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%

Changjiang Pharmaceutical Group Co., Ltd. Profile

About Changjiang Pharmaceutical Group Co., Ltd.

Changjiang Pharmaceutical Group Co., Ltd., together with its subsidiaries, designs, researches, develops, produces, and sells turbochargers in China. It offers turbocharger housing, engine exhaust manifolds, and valve body auto parts, as well as engines. The company also produces and sells solar cell module equipment and photovoltaic modules, as well as engages in the solar energy, lithium batteries, energy storage, and other energy industry businesses. Its products are used in automobiles, construction machinery, agricultural machinery, ship power, generator sets, and other industries. Kangyue Technology Co., Ltd. also exports its products to Americas, Europe, East Asia, and internationally. The company was formerly known as Kangyue Technology Co., Ltd. and changed its name to Changjiang Pharmaceutical Group Co., Ltd. in March 2023. Changjiang Pharmaceutical Group Co., Ltd. was founded in 1963 and is based in Shouguang, China.

CEO
Mr. Ming Luo
Employee
596
Address
Shouguang Economic Development Zone
Shouguang, 262700

Changjiang Pharmaceutical Group Co., Ltd. Executives & BODs

Changjiang Pharmaceutical Group Co., Ltd. Executives & BODs
# Name Age
1 Mr. Ming Luo
GM & Director
70
2 Mr. Luhong Ning
Director, Secretary of the Board of Directors & Deputy GM
70
3 Mr. Yuexiao Yang
Deputy General Manager
70

Changjiang Pharmaceutical Group Co., Ltd. Competitors